Shin, J.L., Teitel, J., Swain, M.G., Bain, V.G., Adams, P.C., Croitoru, K., Peltekian, K., Schweiger, F., Simons, M.E., and Heathcote, E.J. (2005) Virology, Immunology Committee of the Association of Hemophilia Clinic Directors of C. A Canadian Multicenter Retrospective Study Evaluating Transjugular Liver Biopsy in Patients with Congenital Bleeding Disorders and Hepatitis C: Is It Safe and Useful? American Journal of Hematology, 78, 85-93.
http://dx.doi.org/10.1002/ajh.20263

has been cited by the following article:

• TITLE: A Study on the Safety of Liver Biopsy Inpatients with Von Willebrand’s Disease

  AUTHORS: Patrick P. Basu, Niraj J. Shah, Mark M. Aloysius, K. Rayapudi, Robert Brown

  KEYWORDS: Liver Biopsy, vW Disease, Safety, Complications

  JOURNAL NAME: Open Journal of Gastroenterology, Vol.5 No.9, September 24, 2015

  ABSTRACT: Objectives: Liver biopsy remains the gold standard for diagnosis of chronic liver diseases. Outpatient percutaneous biopsy is generally safe with a mortality rate of 0.17% and hospitalization rate for bleeding of 3%. Von Willebrand disease (vWD) syndrome is the most common inherited hematological disorder with a prevalence of 1% - 3% globally. We sought to study whether vWD increases the risk of bleeding for liver biopsies. Methods: All patients (n = 120) who underwent outpatient percutaneous liver biopsies from 1997 to 2007 were analyzed. Demographics, PT/INR, platelet count, vW antigen and ristocetin induced platelet aggregation were studied. Results: No vWD patients had major bleeding that required transfusion, hospitalization or surgery but 9 (75%) had minor local bleeding and all had ecchymosis, which resolved spontaneously within 24 hours. Conclusions: Patients with vW factor deficiency can undergo percutaneous liver biopsy without major bleeding. Minor bleeding may occur at a slightly higher rate. vWD is not a contraindication to percutaneous liver biopsy.